IQVIA Holdings Inc. (NYSE:IQV) Shares Sold by Bank of America Corp DE

Bank of America Corp DE cut its position in IQVIA Holdings Inc. (NYSE:IQVGet Rating) by 3.8% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 891,610 shares of the medical research company’s stock after selling 34,776 shares during the period. Bank of America Corp DE owned 0.47% of IQVIA worth $206,148,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently made changes to their positions in IQV. Clark Capital Management Group Inc. boosted its stake in shares of IQVIA by 3.3% in the fourth quarter. Clark Capital Management Group Inc. now owns 108,168 shares of the medical research company’s stock worth $30,519,000 after acquiring an additional 3,505 shares during the last quarter. Glassman Wealth Services boosted its stake in shares of IQVIA by 23.1% in the fourth quarter. Glassman Wealth Services now owns 277 shares of the medical research company’s stock worth $78,000 after acquiring an additional 52 shares during the last quarter. Rockefeller Capital Management L.P. boosted its stake in IQVIA by 12.4% during the fourth quarter. Rockefeller Capital Management L.P. now owns 7,945 shares of the medical research company’s stock worth $2,240,000 after buying an additional 875 shares during the last quarter. Thames Capital Management LLC boosted its stake in IQVIA by 14.1% during the fourth quarter. Thames Capital Management LLC now owns 59,582 shares of the medical research company’s stock worth $16,810,000 after buying an additional 7,362 shares during the last quarter. Finally, Alerus Financial NA boosted its stake in IQVIA by 6.4% during the fourth quarter. Alerus Financial NA now owns 18,589 shares of the medical research company’s stock worth $5,245,000 after buying an additional 1,117 shares during the last quarter. 86.77% of the stock is owned by institutional investors and hedge funds.

IQVIA Price Performance

IQV stock opened at $199.66 on Wednesday. The company has a current ratio of 0.96, a quick ratio of 0.96 and a debt-to-equity ratio of 2.36. The company has a market capitalization of $37.24 billion, a PE ratio of 33.33, a P/E/G ratio of 1.87 and a beta of 1.34. IQVIA Holdings Inc. has a 12-month low of $194.67 and a 12-month high of $285.61. The business’s fifty day moving average price is $224.67 and its 200 day moving average price is $220.57.

IQVIA (NYSE:IQVGet Rating) last posted its quarterly earnings data on Thursday, July 21st. The medical research company reported $2.44 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.22 by $0.22. IQVIA had a return on equity of 30.21% and a net margin of 8.21%. The firm had revenue of $3.54 billion for the quarter, compared to the consensus estimate of $3.49 billion. During the same quarter in the previous year, the business earned $1.94 EPS. The company’s quarterly revenue was up 3.0% compared to the same quarter last year. On average, sell-side analysts anticipate that IQVIA Holdings Inc. will post 9.4 EPS for the current year.

Analysts Set New Price Targets

A number of research firms have weighed in on IQV. Guggenheim boosted their price objective on IQVIA to $246.00 in a research note on Friday, July 22nd. Barclays lowered their price objective on IQVIA from $255.00 to $235.00 and set an “overweight” rating on the stock in a research note on Monday, September 12th. StockNews.com lowered IQVIA from a “buy” rating to a “hold” rating in a research note on Wednesday. Argus lifted their target price on IQVIA from $260.00 to $275.00 in a research report on Thursday, August 18th. Finally, SVB Leerink initiated coverage on IQVIA in a research report on Friday, July 15th. They issued an “outperform” rating and a $256.00 target price on the stock. Two analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, IQVIA presently has a consensus rating of “Moderate Buy” and an average price target of $275.00.

About IQVIA

(Get Rating)

IQVIA Holdings Inc provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

Featured Articles

Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IQVIA Holdings Inc. (NYSE:IQVGet Rating).

Institutional Ownership by Quarter for IQVIA (NYSE:IQV)

Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.